Targeted HBx gene editing by CRISPR/Cas9 system effectively reduces epithelial to mesenchymal transition and HBV replication in hepatoma cells

Liver Int. 2024 Feb;44(2):614-624. doi: 10.1111/liv.15805. Epub 2023 Dec 17.

Abstract

Background and aims: Hepatitis B virus X protein (HBx) play a key role in pathogenesis of HBV-induced hepatocellular carcinoma (HCC) by promoting epithelial to mesenchymal transition (EMT). In this study, we hypothesized that inhibition of HBx is an effective strategy to combat HCC.

Methodology and results: We designed and synthesized novel HBx gene specific single guide RNA (sgRNA) with CRISPR/Cas9 system and studied its in vitro effects on tumour properties of HepG2-2.15. Full length HBx gene was excised using HBx-CRISPR that resulted in significant knockdown of HBx expression in hepatoma cells. HBx-CRISPR also decreased levels of HBsAg and HBV cccDNA expression. A decreased expression of mesenchymal markers, proliferation and tumorigenic properties was observed in HBx-CRISPR treated cells as compared to controls in both two- and three- dimensional (2D and 3D) tumour models. Transcriptomics data showed that out of 1159 differentially expressed genes in HBx-CRISPR transfected cells as compared to controls, 70 genes were upregulated while 1089 genes associated with cell proliferation and EMT pathways were downregulated.

Conclusion: Thus, targeting of HBx by CRISPR/Cas9 gene editing system reduces covalently closed circular DNA (cccDNA) levels, HBsAg production and mesenchymal characteristics of HBV-HCC cells. We envision inhibition of HBx by CRISPR as a novel therapeutic approach for HBV-induced HCC.

Keywords: CRISPOR; HBV covalently closed circular DNA (cccDNA); cancer stem cells (CSCs); clustered regularly interspaced short palindromic repeats (CRISPR); differentially expressed genes (DEGs); epithelial to mesenchymal transition (EMT); hepatitis B virus (HBV); hepatocellular carcinoma (HCC); small guide RNA (sgRNA); three-dimensional spheroids.

MeSH terms

  • CRISPR-Cas Systems
  • Carcinoma, Hepatocellular* / genetics
  • DNA, Circular
  • Epithelial-Mesenchymal Transition / genetics
  • Gene Editing
  • Hep G2 Cells
  • Hepatitis B Surface Antigens / genetics
  • Hepatitis B virus / genetics
  • Hepatitis B*
  • Humans
  • Liver Neoplasms* / genetics
  • RNA, Guide, CRISPR-Cas Systems
  • Virus Replication

Substances

  • Hepatitis B Surface Antigens
  • RNA, Guide, CRISPR-Cas Systems
  • DNA, Circular